• 
  Aptar to Participate in Upcoming Investor Conferences18 February 2026, 10:00 pm

  CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences

• 
  Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology18 February 2026, 1:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus’ superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structure

• 
  CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference18 February 2026, 1:00 pm

  BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026. About CareDx CareDx is a precision medicine company de

• 
  Catalent and S.Biomedics Announce Partnership to Develop and Manufacture TED‑A918 February 2026, 1:00 pm

  TAMPA, Fla. & SEOUL, South Korea--(BUSINESS WIRE)--Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease. TED‑A9 represents S.Biomedics’ ambition to deliver a new class of regenerative medicine for patients with Parkinson’s disease. The program reflects years

• 
  Scholar Rock to Present at Upcoming Investor Conferences18 February 2026, 1:00 pm

  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Schol

• 
  NeoGenomics to Participate in Upcoming Investor Conferences18 February 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.

• 
  Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference18 February 2026, 12:01 pm

  DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data supporting the potential safety and long-term efficacy of PBGENE-DMD has been selected as a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking plac

• 
  Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March18 February 2026, 12:00 pm

  BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in upcoming investor conferences in February and March.

• 
  Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 202617 February 2026, 10:05 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our

• Advocates Rally at Florida Capitol to Protect Lifesaving HIV Drug Access for Thousands, says AHF17 February 2026, 9:47 pm

  TALLAHASSEE, Fla.--(BUSINESS WIRE)--Advocates Rally at Florida Capitol to Protect Lifesaving HIV Drug Access for Thousands

• 
  Mirada and Angeline Among America's Top Master-Planned Communities of 202517 February 2026, 2:00 pm

  TAMPA BAY, Fla.--(BUSINESS WIRE)--Metro Development Group’s Mirada and Angeline have been named among the nation’s top-selling master-planned communities in 2025, earning recognition from John Burns Research & Consulting and RCLCO, two of the real estate industry’s leading research organizations. Together, the two Pasco County communities ranked in the Top 40 nationally, driven by more than strong sales alone. From Mirada’s 15-acre world-class lagoon–the largest in the U.S.--and vibrant eve

• 
  NeoGenomics Reports Fourth Quarter and Full Year 2025 Results17 February 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.

• 
  NationsBenefits and Kinney Drugs Partner to Expand Flex Card Access for Rx and OTC Health Needs in New York17 February 2026, 12:00 pm

  PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits, the leading healthcare fintech and supplemental benefits platform, announced a new partnership with Kinney Drugs, a trusted, employee-owned pharmacy and retail chain serving communities across New York and Vermont. Through this integration, eligible health plan members will be able to use their NationsBenefits Benefits Mastercard® Prepaid Flex Card at participating Kinney Drugs locations to purchase eligible prescription (Rx) medications, OTC

• 
  BeOne Medicines to Present at Upcoming Investor Conferences17 February 2026, 11:00 am

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Glo

• Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference12 February 2026, 9:30 pm

  ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that the company will present at the Raymond James Institutional Investors Conference in Orlando, Florida on Monday, March 2 at 1:40 p.m. Eastern Time. A live audio webcast of the session will be available at https://investors.guardianpharmacy.com. A replay of the webcast will be accessible shortly after the event and will remain available for 90 days. About Guardian Pharmacy Services Guardian Pharmacy Servi

• Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer12 February 2026, 9:05 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025. Highlights include the following: Revenues were $4.9 million for the quarter and $27.5 million for the year Net loss was $3.2 million for the quarter and $7.7 milli

• 
  Sindre Zeiner-Gundersen Joins Joi Scientific12 February 2026, 7:00 pm

  MERRITT ISLAND, Fla.--(BUSINESS WIRE)--Joi Scientific is pleased to welcome Sindre Zeiner-Gundersen as the company’s Advanced Plasma & Resonant Energy Physicist. Sindre will lead Joi’s scientific activities including all aspects of Joi’s science program. Sindre is a quantum physics expert who previously served as CEO/President of Nornec AS, a Norwegian consulting and engineering services company. Nornec has been a consultant to Joi since 2024. At Nornec, Sindre provided consulting and R&amp

• 
  NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection12 February 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.

• 
  Avanti Capital Advances Impact-Driven Investing and Expands Commitment to Philanthropy12 February 2026, 5:00 am

  BOCA GRANDE, Fla.--(BUSINESS WIRE)--Avanti Capital funds longevity fellowship, expanding its commitment to geroscience research and impact-driven philanthropy.

• Florida Health Dept. Proposes New Formal Rule to Slash HIV Drug Access for Thousands, Notes AHF11 February 2026, 3:19 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Florida Health Dept. Proposes New Formal Rule to Slash HIV Drug Access for Thousands

• 
  HemoSonics’ Quantra Hemostasis System for Obstetric Procedures Named a 2026 Edison Awards Finalist10 February 2026, 1:05 pm

  DURHAM, N.C.--(BUSINESS WIRE)-- #Childbirth--HemoSonics LLC, a medical device company focused on acute bleeding management, today announced that its Quantra® Hemostasis System for Obstetric Procedures is one of the top three finalists in the Women’s Health and Reproductive Innovations category of the world-renowned 2026 Edison Awards. The Company’s point-of-care solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded use of its Quantra Hemostasis System with QStat® Ca

• 
  ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine10 February 2026, 1:00 pm

  WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Series B financing. The financing was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts, as well as existing investors including a multi-national pharm

• Super Buddha to Live Paint at 2026 Hispanic Prosperity Gala on Feb 10th at Mar-a-Lago9 February 2026, 10:38 pm

  PALM BEACH, Fla.--(BUSINESS WIRE)--Venezuelan-born contemporary artist Super Buddha announced today he will present a live painting experience on the red carpet at the Hispanic Prosperity Gala, presented by Latino Wall Street, taking place February 10, 2026, at the Mar-a-Lago Club. This landmark event reflects the growing support of the Latino community for conservative values and their historic turnout for President Donald Trump in the last election. The event will convene a distinguished rost

• Forte Biosciences, Inc. to Present at Upcoming Investor Meetings9 February 2026, 9:01 pm

  DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will

• 
  Trividia Health, Inc. Initiates Labeling Correction for all TRUE METRIX® Blood Glucose Monitoring Systems6 February 2026, 6:00 pm

  FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., announced today that it is initiating a labeling correction which requires a modification of the Owner’s Booklets/System Instructions for Use for all TRUE METRIX, TRUE METRIX AIR, TRUE METRIX GO, and TRUE METRIX PRO Blood Glucose Monitoring Systems (collectively, the “Products”) distributed in the United States, United Kingdom, Mexico, Australia, and the Caribbean. Trividia is updating the E-5 Error Code in the “Messages” section of

• Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 20265 February 2026, 1:00 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and ans

• 
  X‑BATT Files Patent to Advance Safer Lithium-Ion Battery Storage and Operation4 February 2026, 5:59 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--X-BATT today announced it has filed a U.S. patent application covering new materials and designs aimed at improving the safety of lithium-ion batteries during assembly, transportation, operation, and storage. This innovation promotes safer and more resilient batteries in real-world conditions, ultimately focusing on lowering fire risk during deep discharge and extended storage, situations common in homes, vehicles, and warehouses. From smartphones to EVs, lithium

• 
  RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts4 February 2026, 1:00 pm

  SAN MATEO, Calif.--(BUSINESS WIRE)-- #DeepClinicalAI--RapidAI, the pioneer of deep clinical AI and global leader in enterprise imaging, today announced details of 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, held February 4-6, at the Ernest N. Morial Convention Center in New Orleans. The abstracts span aneurysm monitoring, ischemic stroke detection, advanced imaging visualization, and radiology workflow optimization. Findings reflect the impact of deep clinical AI delivered

• 
  Guardant Health to Participate in Upcoming Investor Conferences3 February 2026, 9:05 pm

  PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 10th TD Cowen 46th Annual Health Care Conference in Boston, MA Fireside chat on Wednesday, March 4th at 9:50 a.m. Eastern Time Leerink Partners Global He

• 
  Orthopedic Medical Technology Company Celebrates Grand Opening of U.S. Headquarters With Business, Government and Healthcare Leaders3 February 2026, 7:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)-- #medicaldevice--OSSIO Inc., a fast-growing medical technology company focused on advancing orthopedic surgery with bio-integrative, metal-free fixation implants, celebrated the grand opening of its new U.S. headquarters in Manatee County’s City of Palmetto yesterday with Florida’s lieutenant governor and more than 50 other business, government and healthcare leaders. OSSIO selected Florida to expand its operations, which started in Israel in 2014, because of the state’s compelling

• Florida Health Department Retreats on HIV/AIDS Drug Cuts3 February 2026, 5:57 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--In a notice published earlier today, the Florida Department of Health (DOH) retreated on its decision to make cuts to the State's AIDS drug program, which provides life-saving medications and health insurance support to over 30,000 Floridians living with HIV/AIDS. Alleging that an undocumented $120 million budget shortfall necessitated the cuts, the cuts to the program, originally scheduled to be enacted on March 1st, would adversely impact the life-savin

• 
  Publix Pharmacy Provides Savings on Certain GLP-1 Medications3 February 2026, 3:30 pm

  LAKELAND, Fla.--(BUSINESS WIRE)--Publix Pharmacy is currently offering savings on select GLP‑1 therapies through a discount card program. For a limited time, eligible Publix Pharmacy customers can have their prescriptions for the newly introduced Wegovy (semaglutide) 1.5 mg or 4 mg tablet filled at pricing starting as low as $149 per month, and Wegovy and Ozempic (semaglutide) 0.25 mg and 0.5 mg injectables starting as low as $199 per month. Obtaining the reduced price Customers can speak with

• 
  RxUtility and Buzz Health Partner to Boost Medication Price Transparency for Consumers3 February 2026, 2:15 pm

  NASHVILLE, Tenn. & FORT WALTON BEACH, Fla.--(BUSINESS WIRE)-- #AffordabilityCrisis--RxUtility, a medication affordability toolkit, announced a partnership with Buzz Health, leveraging its RxCompare multi-discount card pricing API.

• 
  Family Heart Foundation Teams Up with Former NFL Quarterback Matt Hasselbeck to Launch “Tackle Cholesterol™: Get into the LDL Safe Zone®”3 February 2026, 1:03 pm

  FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #HeartMonth--Former NFL quarterback, Matt Hasselbeck, and the Family Heart Foundation team up to raise awareness of high cholesterol as a risk for heart disease.

• 
  Massive Bio Launches TrialRelay™ at SCOPE 2026: An Operating System to End "Referral Black Holes" in Oncology2 February 2026, 2:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Massive Bio today announced the launch of TrialRelay™, a physician-facing enrollment orchestration platform designed to eliminate one of oncology’s most persistent failures: patients getting lost after a clinical trial referral. The announcement will be made during the SCOPE Conference 2026, the leading global forum for clinical operations and innovation. For years, Massive Bio’s physician platform operated under the name Clinical Network. While accurate, the ter

• 
  Boyd to Exhibit at Medical Design & Manufacturing (MD&M) West 2026 in Anaheim, California2 February 2026, 1:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)-- #Boyd--Boyd, a leader in advanced materials and medical wearable solutions, will exhibit at MD&M West, taking place February 3 -5, 2026 in Anaheim, California. Boyd experts will be on site to highlight the latest advancements in stick-to-skin biosensors, medical wearables, display technologies, and medical-grade disposables. With deep expertise in materials science and precision engineering, Boyd partners with leading healthcare innovators to develop patient focu

• AHF Receives Expedited Florida Hearing Opposing ADAP Reductions31 January 2026, 12:32 am

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--AHF Receives Expedited FL Hearing Opposing ADAP Reductions

• 
  Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)30 January 2026, 9:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of common stock. Awards were made to 20 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee

• Not On Our Watch! AHF Continues to Stand Up Against Florida Eliminating HIV/AIDS Care30 January 2026, 3:06 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--In continuing to stand up against the proposed cuts to Florida’s AIDS Drug Assistance Program (ADAP), advocates with AIDS Healthcare Foundation (AHF) will host simultaneous protests at the local department of health offices in Orlando, Florida and St. Petersburg, Florida. Taking place at 10:30am ET on Friday, January 30, 2026, the protests will take place at 205 Dr. Martin Luther King, Jr. Street North, St. Petersburg, FL and 932 W. Central Blvd., Orlando

• 
  Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy29 January 2026, 12:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy. The FDA

• 
  CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results28 January 2026, 9:05 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to dilute

• 
  New UCF Research Indicates C-BATT’s Obsidia™ Swells Less Than Graphite During Lithiation28 January 2026, 4:13 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--As global demand increases for affordable, longer-lasting, high-capacity energy storage, new research suggests C-BATT’s Obsidia™ could help solve one of the most persistent causes of failure in lithium-ion batteries: material swelling during cycling. University of Central Florida (UCF) professor Dr. Akihiro Kushima, a leader in the field of in situ transmission electron microscopy, presented the findings at the 50th Annual International Convention and Expo on Adv

• 
  I/ONX and Mote Marine to Collaborate on Incorporating AI Compute into Marine Science Research28 January 2026, 2:00 pm

  LAS VEGAS & SARASOTA, Fla.--(BUSINESS WIRE)--I/ONX High Performance Compute and Mote Marine Laboratory, Inc. are partnering to incorporate AI and heterogeneous compute into marine research.

• 
  Medable Introduces AI Agent to Reduce Burden at Research Sites By Assisting Principal Investigators with Oversight of eCOA Data28 January 2026, 12:00 pm

  PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data. Medable’s newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable’s TMF and CRA agents, its PI Summary Agent continues the company’s rapid rollout of fun

• 
  Premier Radiology Services Acquires NRAD, Further Expanding Teleradiology Capabilities28 January 2026, 11:30 am

  DEERFIELD BEACH, Fla.--(BUSINESS WIRE)--Premier Radiology Services Acquires NRAD, Further Expanding Teleradiology Capabilities

• UF Health Transplant Specialties Again Rank Among Nation’s Best27 January 2026, 3:28 pm

  GAINESVILLE, Fla.--(BUSINESS WIRE)--UF Health transplant programs continue to be among the nation’s elite, including best-in-category results for the UF Health lung transplant program, according to reports released earlier this month by the Scientific Registry of Transplant Recipients, or SRTR. “Treatment at UF Health centers on individualized care, quality of life and long-term outcomes,” said Thiago Beduschi, M.D., director of the Abdominal Transplant Center. “That means providing patients wi

• 
  AdhereTech Appoints Jeremy Gilbert as CEO to Accelerate Growth Across Clinical Trials and Commercial Adherence Programs27 January 2026, 1:00 pm

  SUMMIT, N.J.--(BUSINESS WIRE)--AdhereTech, a leader in real-time medication adherence smart devices, today announced the appointment of Jeremy Gilbert as chief executive officer. Gilbert, who previously served as AdhereTech’s chief product development officer, brings more than 20 years of experience building and scaling digital health, life sciences, and enterprise technology solutions that improve patient outcomes and protect critical research and commercial investments. The appointment reflec

• 
  NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 202627 January 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.

• 
  Legislation In Florida Seeks To Increase Access To Genetic Testing22 January 2026, 10:05 pm

  TALLAHASSEE, Fla.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, commends Senator Ana Maria Rodriguez (R-Doral) and Representative Marie Woodson (D-Pembroke Pines) for introducing legislation that would eliminate financial barriers for patients requiring clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing. Germline testing is a type of test that looks for inherited mutations that have been present

• 
  Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES22 January 2026, 12:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)-- #ConceptMedical--Concept Medical Inc. is proud to announce the successful enrollment of the first patients in the STARS DAPT randomized controlled trial.

• 
  Starfighters Completes Wind Tunnel Testing for STARLAUNCH 121 January 2026, 1:00 pm

  CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the innovative aerospace company, owner and operator of the world's largest fleet of commercial supersonic aircraft, today announced the successful completion of wind tunnel testing for STARLAUNCH 1, a key technical milestone in the Company’s air-launched rocket development efforts. The completed test campaign evaluated separation of the STARLAUNCH 1 vehicle from the Starfigh

• 
  SurGenTec® Secures FDA Clearance for ION-C™ Facet Fixation System — Designed to Support Fusion While Preserving Alignment20 January 2026, 7:32 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--SurGenTec®, a medical device innovation company focused on advancing treatment options for orthopedic and spine surgery, today announced FDA clearance of its ION-C™ Facet Fixation System. ION-C™, part of SurGenTec®’s posterior cervical platform, has received expanded indications allowing for the treatment of cervical pseudoarthrosis when implanted bilaterally within the facet joints. This clearance is supported by compelling long-term clinical evidence from an

• 
  Smart Meter Launches iGlucose® Touch, a Touchscreen, Cellular-Connected Blood Glucose Meter Built for Modern RPM20 January 2026, 2:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--As demand accelerates for simpler, more reliable remote patient monitoring solutions, Smart Meter, the leading supplier of cellular-enabled Remote Patient Monitoring (RPM) devices, data, and services, today announced the launch of iGlucose® Touch, a next-generation blood glucose monitoring system engineered to modernize glucose testing while delivering dependable, real-time data to care teams. Purpose-built for RPM, iGlucose Touch addresses long-standing challenges

• 
  VB Spine to Acquire Intraoperative Visualization Platform From Robotron Surgical Technologies15 January 2026, 1:58 pm

  NEW YORK & MIAMI--(BUSINESS WIRE)--VB Spine announced an agreement to acquire the SpineHawk™ intraoperative spinal visualization platform from Robotron Surgical Technologies.

• 
  ERMA Systems Launches Q1 AI Pilot with Life Science Innovators, Welcomes Brandon Schlette to Advisory Board15 January 2026, 1:00 pm

  MIAMI--(BUSINESS WIRE)--ERMA Systems™, the AI-powered compliance platform redefining how life-sciences companies manage medical, legal, and regulatory (MLR/PRC) review, announced today that multiple organizations will participate in its Q1 2026 pilot program—an 8–10-week evaluation designed to validate ERMA’s technology in real-world pharmaceutical workflows. In a major step forward for its governance and industry leadership, ERMA Systems also announced that Brandon Schlette, Senior Commercial

• 
  PsiQuantum Collaborating with Airbus to Advance Quantum Computing for Aerospace13 January 2026, 2:00 pm

  PALO ALTO, Calif.--(BUSINESS WIRE)--PsiQuantum is collaborating with Airbus to advance applications in aerospace for fault-tolerant quantum computers.

• 
  StarLIMS Announces Strategic Investment by Turn/River Capital13 January 2026, 2:00 pm

  HOLLYWOOD, Fla.--(BUSINESS WIRE)--StarLIMS, a global enterprise informatics platform for laboratories, today announced a strategic investment by Turn/River Capital, a leading software private equity firm. Existing investor Francisco Partners will exit its investment as a result of this transaction. StarLIMS powers manufacturing and research lab operations worldwide. The company enables greater data automation and visibility, regulatory control, and workflow management, with a product suite that

• 
  Publix Announces New Vice President of Pharmacy12 January 2026, 4:34 pm

  LAKELAND, Fla.--(BUSINESS WIRE)--Today, Publix Super Markets CEO Kevin Murphy announced the promotion of Katie Scanlon to vice president of pharmacy, effective Feb. 1, 2026. “We are proud to have Katie take the next step in her Publix career,” commented Murphy. “Promotion from within provides our associates with amazing opportunities for growth and development. Katie has been an exceptional leader dedicated to growing and mentoring her team to best serve our customers. I am excited to see the c

• Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus12 January 2026, 1:00 pm

  BERLIN & NAPLES, Fla.--(BUSINESS WIRE)--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m), two investigational molecular imaging agents for the diagnosis of cardiac a

• 
  NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue12 January 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s Chief Financial Officer.

• 
  SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs12 January 2026, 12:00 pm

  TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies

• 
  Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)12 January 2026, 11:15 am

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). “We believe exploring new mec

• 
  Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC12 January 2026, 11:00 am

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for ivonescimab, the novel, first-in-class investigational bispecific antibody, in combination with chemotherapy in second-line or later treatment of patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-

• 
  Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)10 January 2026, 1:16 am

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock. Awards were made to seventeen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Co

• 
  CONMED Corporation Announces Chief Financial Officer Transition8 January 2026, 9:55 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026. CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer. “On behalf of our Board and leadership team, I

• New Study Shows How Florida Can Strengthen Public Trust and Cooperation in Future Pandemics8 January 2026, 8:03 pm

  MIAMI--(BUSINESS WIRE)-- #COVID19--A new study from the University of Miami Public Health Policy Lab and the AHF Global Public Health Institute sheds light on why public trust broke down during the COVID-19 pandemic—and what can be done to rebuild it before the next health emergency. Drawing on interviews with government, academic, and private-sector leaders across Florida, the study found that distrust in public health grew due to a lack of transparency, political tensions, and inconsistent communication

• Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco7 January 2026, 9:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference. “With recently established coding by the Centers for

• 
  Ametris reports significant momentum with global pharma leaders7 January 2026, 8:37 pm

  PENSACOLA, Fla.--(BUSINESS WIRE)--Ametris today reported significant momentum with the pharmaceutical industry, including partnerships with eight of the top ten companies.

• Sensus Healthcare Appoints Larry Biscotti to its Board of Directors7 January 2026, 1:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of

• 
  FDA and EMA Grant Orphan Drug Designation for Curadel’s CPI-008, a Targeted Zwitterionic Imaging Drug for Pancreatic Cancer7 January 2026, 1:00 pm

  BONITA SPRINGS, Fla.--(BUSINESS WIRE)--Curadel's novel targeted zwitterionic surgical imaging drug for pancreatic cancer has been granted Orphan Drug Designation by the FDA and the EMA.

• 
  Kincell Bio Promotes Industry Veteran Larry Pitcher to Chief Executive Officer to Propel Expansion and Client Impact in Cell Therapy Manufacturing6 January 2026, 1:00 pm

  RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, is pleased to announce the promotion of Lawrence “Larry” Pitcher to Chief Executive Officer, effective immediately. Pitcher succeeds Mark R. Bamforth OBE, who guided the company through a successful phase of growth as CEO and will continue to support the transition in a strategic capacity as Executive Chair of the Board. The year of 2025 has been tran

• 
  DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)6 January 2026, 12:45 pm

  MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced positive results from its Phase 1 multiple ascending dose (MAD) study of DMX-1001 (oral noribogaine) for the treatment of alcohol use disorder (AUD). The results demonstrated safety, tolerability, and pharmacokinetics that support advancing DMX-1001 to Phase 2 clinical trials in people with AUD. The Phase 1 clinical trial was a double-blind, placebo-

• 
  Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference6 January 2026, 12:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organization, includ

• 
  CONMED Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference5 January 2026, 9:10 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, January 12, 2026 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.conmed.com and

• 
  CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 20265 January 2026, 9:05 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter 2025 after the market close on Wednesday, January 28, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed

• 
  NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference5 January 2026, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

• 
  Promesa y Esperanza® Broadcast Rallies Hispanic Media, Artists, and Fans to Support St. Jude Children's Research Hospital30 December 2025, 10:57 pm

  MEMPHIS, Tenn.--(BUSINESS WIRE)--The St. Jude Promesa y Esperanza® (Promise and Hope) broadcast earlier this month brought together Hispanic media leaders, Latin music artists, and Spanish-speaking audiences to support research and treatment at St. Jude Children’s Research Hospital®. The event, part of the Music Gives to St. Jude Kids initiative, raised $5.2 million. Spanish-language media outlets, including Uforia, iHeart, and Latino Media Group, mobilized radio stations across 15 major market

• 
  Biobeat Secures $50 Million Series B Financing to Advance Commercialization of its Patch-worn, Cuff-less 24-hour Ambulatory Blood Pressure Monitor30 December 2025, 9:39 pm

  PETAH TIKVA, Israel & BOCA RATON, Fla.--(BUSINESS WIRE)-- #24hourABPM--Biobeat closed a $50M Series B, led by Ally Bridge, OrbiMed, and Elevage, to expand U.S. commercialization of its 24 hour FDA-cleared ABPM.

• 
  NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors30 December 2025, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors.

• 
  Akumin Announces Agreement that will Solidify Long-Term Financial Foundation to Support Continued Growth and Patient Care23 December 2025, 9:00 pm

  PLANTATION, Fla.--(BUSINESS WIRE)--Akumin Inc. (together with its subsidiaries “Akumin” or the “Company”) announced today that it entered into an agreement (the “Support Agreement”) with certain noteholders representing over 95% of outstanding senior secured notes due in 2027 and 2028 (together, the “Senior Secured Notes”), and Stonepeak, a leading alternative investment firm, that will reduce debt, enhance liquidity and extend its debt maturities related to the Senior Secured Notes. Under the

• 
  FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23 December 2025, 5:07 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate

• 
  VOKA Announces Free 1-Month Access to a Pro Subscription for New Users23 December 2025, 1:00 pm

  ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- #3DAnatomy--VOKA provides one-month free access to VOKA 3D Anatomy & Pathology, a high-precision 3D atlas for medical education and clinical professionals.

• 
  National Beverage Advocates Giving the Children of St. Jude . . . ‘A Chance at a Lifetime’18 December 2025, 3:00 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Commemorating its 32nd year as a continuing partner of St. Jude Children’s Research Hospital®, National Beverage Corp. (NASDAQ: FIZZ), advocates unconditional support of St. Jude’s mission to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. “The philosophy driving St. Jude is ‘Every child deserves a chance to . . . live.’ I personally am grateful that for more than 30 years, God has blessed me wit

• 
  Smart Meter Introduces First Handheld Cellular-Connected Thermometer for Effortless Patient Monitoring18 December 2025, 2:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leader in cellular-enabled remote patient monitoring (RPM) solutions, is proud to announce the launch of the first handheld, fully cellular-enabled thermometer. Designed to capture and transmit temperature data in real time, it works directly over cellular networks, with no need for a hub, Wi-Fi, or Bluetooth. This breakthrough makes remote patient monitoring faster, simpler, and more reliable for both providers and patients. The new device is call

• 
  A.R.I. Founder Dr. Zack Ellison Earns Doctorate from the University of Florida Establishing Landmark Venture Debt Research17 December 2025, 5:06 pm

  TAMPA, Fla. & ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- #ARI--Applied Real Intelligence (“A.R.I.”), a leading provider of growth credit and venture debt to North American innovators, announced today that its Founder and Managing General Partner, Dr. Zack Ellison, has earned a Doctor of Business Administration (DBA) from the University of Florida’s Warrington College of Business. His doctoral research, Venture Debt: An Empirical Study of Loan-Level Pricing and Stock-Level Performance, establishes the fir

• 
  Publix Pharmacy Is Now Providing Customers With a Prescription Savings Finder17 December 2025, 4:57 pm

  LAKELAND, Fla.--(BUSINESS WIRE)--Publix launched a new prescription savings finder tool to help customers save money on prescription medications. Discount Finder, powered by RxSense, is now available on the Publix Pharmacy app or by visiting publix.com/rxsavings. The Discount Finder provides customers with a quick and easy way to find lower prices on most prescriptions at Publix Pharmacy. “Discount Finder is a digital marketplace that provides a single location for customers to search for savin

• 
  Voloridge Health Announces Sponsorship of World Champion Speed Skater Jordan Stolz17 December 2025, 3:55 pm

  JUPITER, Fla.--(BUSINESS WIRE)--Voloridge Health, LLC, a data science company dedicated to empowering individuals and organizations to transform health with data-driven insights, is proud to announce a strategic partnership with World Champion speed skater Jordan Stolz. At just 21 years old, Stolz has quickly established himself as one of the most dominant figures in long track speed skating. The current world record holder in the 1000m, he captured the 2024 World Allaround Championships to bec

• 
  Biocerta Precision Diagnostics Announces Exclusive Licensing Agreement With the University of Miami and Strategic Development Partnership With Acumen Partners17 December 2025, 2:15 pm

  PITTSBURGH--(BUSINESS WIRE)-- #cancer--Biocerta Precision Diagnostics, Inc., a biotechnology company pioneering functional drug sensitivity testing (DST) to personalize cancer therapy, today announced two major business milestones: (1) an exclusive licensing agreement with the University of Miami covering core intellectual property assets which contribute to Biocerta’s DST technology, and (2) a strategic development and commercialization agreement with Acumen Partners to support the Company through early

• Cardone Ventures Announces Unsolicited $4.25 Per Share All-Cash Proposal to Acquire PetMed Express16 December 2025, 5:04 pm

  MIAMI--(BUSINESS WIRE)--Cardone Ventures, backed by billionaire investor, Grant Cardone and his business partners Brandon and Natalie Dawson, today announced that it has submitted an unsolicited, non-binding proposal to acquire PetMed Express, Inc. (Nasdaq: PETS) (“PetMeds”) for $4.25 per share in cash, representing an implied equity value of approximately $89 million. The proposal was delivered to the Board of Directors of PetMed Express and is not subject to any financing contingency, reflect

• 
  Kalogon Opens $50M Production Facility, Expands Team as Revenue Doubles16 December 2025, 2:00 pm

  MELBOURNE, Fla.--(BUSINESS WIRE)--Smart seating leader Kalogon has expanded to a dedicated manufacturing facility with a $50 million production capacity following revenue growth.

• 
  Reimagine Care and Tampa General Hospital Cancer Institute Launch Virtual Cancer Care Collaboration to Reduce Hospitalizations and Elevate Patient Support16 December 2025, 1:00 pm

  NASHVILLE, Tenn. & TAMPA, Fla.--(BUSINESS WIRE)--Reimagine Care, the leader in on-demand, technology-enabled cancer care, today announced a collaboration with the Tampa General Hospital (TGH) Cancer Institute to expand access, increase clinical capacity and improve cancer care delivery across the Tampa Bay region. The partnership integrates Reimagine Care’s AI-enabled virtual cancer care program into Tampa General’s clinical pathways, supporting the Institute’s long-term strategy to scale oncol

• 
  Algia Pharma Gains FDA Support to Advance Novel Non-Opioid Pain Treatment Toward a Phase 2 Clinical Trial After IND-Enabling Studies With Indication Expanded to All Mild-to-Moderate Acute Pain15 December 2025, 12:30 pm

  BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the company has received support from the U.S. Food and Drug Administration (FDA) to advance AlgiaPak® toward a Phase 2 clinical trial upon completion of Investigational New Drug (IND)-enabling studies. AlgiaPak is the company’s streamlined, multimodal pain formulation designed to treat all mild-to-moderate acute pain as effectively as opioids, without exposing patients to the risk of opioid addiction. The company ha

• 
  NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation15 December 2025, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.

• 
  26Health Expands Partnership with NuvemRX to Open First Entity-Owned Pharmacy11 December 2025, 2:00 pm

  SHARON HILL, Pa.--(BUSINESS WIRE)--26Health, a Central Florida-based family health center committed to providing comprehensive care to underserved communities, today announced plans to open its first entity-owned pharmacy in Orlando. This initiative is being made possible through an expansion of the health center’s partnership with NuvemRx, a leading tech-enabled pharmacy service for community health providers. Healthcare providers often face significant challenges in standing up and optimizing

• 
  NeoGenomics to Present New ctDNA Research at SABCS 202510 December 2025, 12:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.

• 
  Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting9 December 2025, 12:30 pm

  BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared first-in-human data from the ongoing inMMyCARTM study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida. Highlights o

• 
  O.N.E Amazon calls for biodiversity to be treated as critical global infrastructure at the Nobel Sustainability Trust Summit 20259 December 2025, 12:03 am

  MIAMI--(BUSINESS WIRE)--O.N.E Amazon calls for biodiversity to be treated as critical global infrastructure at the Nobel Sustainability Trust Summit 2025

• 
  From Novel Therapies to First-in-Human Trials, City of Hope Advances Blood Cancer Care at the American Society of Hematology (ASH) Annual Conference8 December 2025, 10:30 pm

  LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland

• 
  Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia8 December 2025, 9:30 pm

  WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET

• 
  Qihan Biotech Presents New Clinical Data on Allogeneic CAR-T Cell Therapies and Preclinical Data on In Vivo CAR-T at the American Society of Hematology (ASH) Annual Meeting8 December 2025, 9:30 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and cancer, including allogeneic CAR-T and in vivo CAR-T therapies, presented an oral and several poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting. The data included encouraging clinical results with the company’s allogeneic CAR-T program and foundational preclinical work supporting its emerging in vivo CAR-T pr

• 
  Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)8 December 2025, 9:30 pm

  COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter transformation (RT), a rare complication in which chronic lymphocytic leukemia (CLL) evolves into an aggressive lymphoma

• 
  Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting8 December 2025, 5:00 pm

  NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic, today presented interim data from the ongoing Phase 1/2 clinical trial evaluating ulviprubart (ABC008) in patients with T cell large granular lymphocytic leukemia (T-LGLL) with anemia and/

• 
  MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival8 December 2025, 5:00 pm

  LYON, France--(BUSINESS WIRE)---- $MAAT #ASH--MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival.

• 
  Genetix Presents Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation at the 67th American Society of Hematology (ASH) Annual Meeting8 December 2025, 2:30 pm

  SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLO™ and LYFGENIA™, first-in-class ex vivo gene addition therapies for the treatment of beta-thalassemia and sickle cell disease. With over 250 patients treated with these therapies, inclusive of clinical trials and commercial treatments, and long-term follow-up data beyond 10 years, Genetix has the most robust long-term dataset in ex vivo gene therapy for

• 
  Opna Bio Showcases Multi-Functional Degraders with Potent Anti-Myeloma Activity and Encouraging Spleen Reductions in Patients with Myelofibrosis Treated with OPN-2853 and Ruxolitinib8 December 2025, 2:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced promising preclinical data from the company’s novel, multi-functional protein degrader program and positive updated data from an ongoing Phase 1 combination study with OPN-2853, a bromodomain and extra-terminal motif (BET) inhibitor, as an add-on to ruxolitinib in patients with advanced myelofibrosis. Data were shared in an oral

• 
  NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 20258 December 2025, 1:05 pm

  FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.

• 
  BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8 December 2025, 1:00 pm

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At

• 
  Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia8 December 2025, 1:00 pm

  BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153 for Acute Myeloid Leukemia

• 
  Children’s Hospital Los Angeles Researchers Identify Markers at Birth Linked to Childhood Leukemia Risk8 December 2025, 12:00 pm

  LOS ANGELES--(BUSINESS WIRE)--A new study led by Children’s Hospital Los Angeles has linked specific molecular markers at birth to future childhood leukemia risk.

• 
  Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies7 December 2025, 11:00 pm

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses

• 
  Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA7 December 2025, 2:30 pm

  WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

• 
  Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 20257 December 2025, 2:30 pm

  WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025

• 
  Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma7 December 2025, 12:50 pm

  COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study showed that treatment with EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.14-0.31, p<0.0001) compared to standard

• 
  HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors6 December 2025, 10:15 pm

  NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no tr

• 
  Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6 December 2025, 2:30 pm

  OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. The results were presented by Ionis Pharmaceuticals

• 
  Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)6 December 2025, 2:30 pm

  COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Results from two arms of the EPCORE® NHL-2 trial, evaluating first-line, fixed-treatment dur

• 
  NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 20256 December 2025, 1:35 pm

  MINNEAPOLIS--(BUSINESS WIRE)--New research from NMDP, a global nonprofit leader in cell therapy, and conducted by CIBMTR® (Center for International Blood and Marrow Transplant Research®) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla., demonstrates that patients receiving allogeneic transplantation using more deeply mismatched unrelated donors (MMUD), followed by post-transplant chemotherapy, can achieve outcomes comparable to those receiving tran

• 
  Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program &amp; Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation6 December 2025, 12:05 pm

  SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets sub

• 
  Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5 December 2025, 9:30 pm

  MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committe

• 
  CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines5 December 2025, 1:00 pm

  LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. “Today’s announcement reflects a positive step in our strategic portfolio review and o

• 
  Ossium Health to Present New Clinical Data on Its Organ Donor Bone Marrow at ASH 20255 December 2025, 10:00 am

  SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health will present new clinical outcomes data at ASH 2025, highlighting the potential of organ donor bone marrow as a promising graft source.

• 
  Introducing Outcomes Insights: A New Standard for Pharmacy Intelligence4 December 2025, 8:00 pm

  ORLANDO, Fla.--(BUSINESS WIRE)--Outcomes® is formalizing the availability of Outcomes Insights, an advanced reporting platform that provides pharmacies with comprehensive visibility into their performance. Currently exclusive to Rx30 users, the solution equips teams with actionable intelligence to enhance operational efficiency and business health. “Outcomes Insights represents a major step forward in helping pharmacies unlock actionable intelligence,” said Jon Grice, VP, Pharmacy Insights for

• 
  Mission Bio’s Tapestri Single Cell Multi-Omics Platform for Exploratory Biomarker Analysis Supports Myeloproliferative Neoplasms (MPNs) Data Presentation at ASH 20254 December 2025, 2:00 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, Inc., a leader in single-cell multi-omic solutions for precision medicine, announced that its Tapestri Platform and custom assay development supported initial exploratory biomarker analysis data presented by Incyte at the ASH 2025 conference in Orlando, Florida, in December. The data demonstrate Tapestri® Platform’s ability to accelerate the understanding of Myeloproliferative Neoplasms (MPNs) disease biology at the single-cell level. M

• 
  Arima Genomics Reports New Data at ASH 2025 Supporting More Complete Rearrangement Profiling in DLBCL With Hi-C Technology Used in Aventa Lymphoma4 December 2025, 1:00 pm

  CARLSBAD, Calif.--(BUSINESS WIRE)-- #ASH--Arima Genomics, a company leveraging whole-genome sequence and structure information, today announced new data to be presented at ASH.

• 
  AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH4 December 2025, 12:00 pm

  WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025. This year’s ASH congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key presentations include: Phase I trial of surovatamig: Updated r

• 
  Vycellix Prepares for First-in-Human Study of Novel Allogeneic Cell Therapy Powered by Its Universal Cell Engineering Platform3 December 2025, 5:00 pm

  BOCA RATON, Fla. & STOCKHOLM--(BUSINESS WIRE)-- #ASH25--Vycellix advancing breakthrough discovery to human study with aim to redefine paradigm for transplant medicines, eliminating risk of graft rejection.

• 
  Catalyst OrthoScience Receives FDA 510(k) Clearance for Expanded Indications of the Fracture Shoulder System3 December 2025, 3:00 pm

  NAPLES, Fla.--(BUSINESS WIRE)--Expanded indications provide surgeons flexibility for better patient outcomes, reinforcing Catalyst’s role as a leader in next-gen shoulder solutions.

• 
  New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting3 December 2025, 1:00 pm

  AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies. The datasets include an oral presentation on a retrospective

• 
  New Family Heart Foundation Study Finds Only 13% of Adults With Cardiovascular Disease Achieve Comprehensive LDL-C Management3 December 2025, 1:00 pm

  FERNANDINA BEACH, Fla.--(BUSINESS WIRE)--The Family Heart Foundation, a leading research and advocacy organization, published new research in the American Journal of Preventive Cardiology revealing significant gaps in cholesterol management during 2022-23 among U.S. adults with atherosclerotic cardiovascular disease (ASCVD). Findings show that only 13% of adults with ASCVD were meeting three key components of optimal low-density lipoprotein-cholesterol (LDL-C) management, including receiving gu

• 
  Trividia Health, Inc. Announces Preferred Listing of the TRUE METRIX® Blood Glucose Meters and Test Strips on the Express Scripts Commercial National Preferred Formulary2 December 2025, 5:33 pm

  FT. LAUDERDALE, Fla.--(BUSINESS WIRE)-- #TRUEMETRIX--Trividia Health, Inc., announced today that it’s TRUE METRIX® Self-Monitoring Blood Glucose Systems are preferred for commercial patients on the Express Scripts National Preferred Formulary in the United States, effective October 1st, 2025. The TRUE METRIX® portfolio provides a level of performance rooted in science, research and technological advancements. TRUE METRIX test strips feature TRIPLE SENSE TECHNOLOGY®, which ensures proven accuracy and confiden

• 
  ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model2 December 2025, 3:05 pm

  WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella Pertussis, today announced the peer-reviewed publication of Phase 2b trial results in The Lancet Microbe (Link). The published research article summarizes the CHAMPION-1 clinical study of BPZE1, a randomized, double-blind, placebo-controlled study conducted in healthy adults in a controlled human infection model. BP

• 
  CytoAgents Announces Poster Presentation of New CTO1681 Clinical Data at the 67th American Society of Hematology Annual Meeting2 December 2025, 2:05 pm

  PITTSBURGH--(BUSINESS WIRE)-- #ASH25--CytoAgents announced a poster presentation of new CTO1681 clinical data at the 67th American Society of Hematology Annual Meeting.

• 
  Findings from Ontada’s Real-World Study: Maintaining Hemoglobin Levels &gt;10 g/dL in Patients with Myelodysplastic Syndrome is Associated with Significantly Improved Overall Survival2 December 2025, 1:15 pm

  BOSTON & ORLANDO, Fla.--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to real-world oncology data and insights, will present findings from a retrospective cohort study at ASH 2025.

• 
  Sarah Cannon Research Institute to Present Research on Advances in Blood Cancers and Blood Disorders at 2025 ASH Annual Meeting &amp; Exposition2 December 2025, 1:00 pm

  NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today that it will showcase its latest research through 100 abstracts and presentations at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in Orlando, Florida and virtually from December 6-9. SCRI’s expansive network is represented by more than 50 researchers who ser

• 
  Owens &amp; Minor to Present at Upcoming Investor Conferences on December 2, 20252 December 2025, 12:00 pm

  RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global Healthcare Conference On Tuesday, December 2, 2025, Ed Pesicka, the Company’s President and Chief Executive Officer, and Will Parrish, the Company’s Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and h

• 
  Genomic Testing Cooperative (GTC) to Share 12 Ground-breaking Abstracts at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando2 December 2025, 12:00 pm

  LAKE FOREST, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, today announced that its work and data will be presented in 12 abstracts at the ASH 2025 Annual Meeting in Orlando, December 6-9. The work represents novel proprietary approaches using artificial intelligence (AI) for prediction models, transcriptomic signatures, cell-free RNA (cfRN

• 
  Akumin Expands Akumin AXIS™ Line with New 1.5T MRI and Akumin AXIS Drop Trailer1 December 2025, 6:00 pm

  PLANTATION, Fla.--(BUSINESS WIRE)-- #Akumin--Akumin today announced the debut of two major advancements in its Akumin AXIS™ line of relocatable imaging suites at the 2025 Radiological Society of North America (RSNA) annual meeting. The company unveiled the Akumin AXIS 1.5T MRI and introduced the Akumin AXIS Drop Trailer (patent-pending), the first design of its kind in the U.S. and a new evolution in Akumin’s industry-leading mobile imaging portfolio. Together, these new configurations highlight Akumin’s

• 
  Kaplan Survey: Nearly 9 in 10 Medical Schools Expect Fierce Competition Again This Admissions Cycle1 December 2025, 1:55 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #doctors--Kaplan survey: 89 percent of medical school admissions officers say aspiring doctors are in the midst of another highly competitive admissions cycle.

• 
  Nuvation Bio to Participate in Upcoming Investor Conferences26 November 2025, 9:05 pm

  NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences: 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL

• 
  Smart Meter Opinion Editorial: Remote Patient Monitoring Works. UnitedHealthcare’s 2026 Rollback Ignores the Evidence, and Patients Will Pay the Price.26 November 2025, 2:00 pm

  TAMPA, Fla.--(BUSINESS WIRE)--The following is an opinion editorial provided by Casey Pittock, CEO, Smart Meter: UnitedHealthcare’s decision to sharply limit remote patient monitoring (RPM) reimbursement beginning January 1, 2026, to heart failure and hypertensive disorders of pregnancy, is a disservice to clinicians, patients, and the healthcare system at large. It contradicts federal momentum to modernize chronic care and misrepresents the weight of current evidence on RPM’s clinical value fo

• 
  Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting26 November 2025, 1:30 pm

  SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) du

• AdaptHealth Corp. to Participate in Upcoming Investor Conference26 November 2025, 1:30 pm

  CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the BofA Securities Leveraged Finance Conference, being held in Boca Raton, FL, on Tuesday, December 2, 2025, including a fireside chat at 8:10 a.m. ET. The webcast link will be available on the Com

• 
  U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26 November 2025, 11:00 am

  SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is a

• 
  Former Latin American Presidents Join Experts for High-Level Panel on Future Health Preparedness25 November 2025, 3:00 pm

  MEXICO CITY--(BUSINESS WIRE)-- #COVID19--The AHF Global Public Health Institute for Latin America and the Caribbean, in collaboration with the University of Miami Public Health Policy Lab, invites members of the press to a high-level virtual panel titled “Why Should Latin America Act as a Bloc in Future Health Emergencies? Toward a Common Regional Preparedness and Response Agenda.” Latin America has been among the regions most affected by recent health crises—including the COVID-19 pandemic and the 2024 d

• 
  Evercore Hosts 8th Annual Healthcare Conference, Dec. 2-4, 202525 November 2025, 1:00 pm

  NEW YORK--(BUSINESS WIRE)--Evercore (NYSE: EVR) will host its 8th annual Healthcare Conference at the Loews Coral Gables Hotel in Coral Gables, Florida, Dec. 2-4, 2025. This year’s conference features over 500 industry experts and corporate leaders from more than 200 leading healthcare companies. Across three days, guests will have the opportunity to attend panels, fireside chats, scheduled investor meetings and company-hosted dinners while directly engaging with key industry professionals. The

• 
  CAN Community Health Presents World AIDS Day Concert Featuring Broadway Legends Adam Pascal &amp; Anthony Rapp25 November 2025, 1:00 pm

  FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #PrEP--CAN Community Health is proud to present its 2025 World AIDS Day Concert, an inspiring night of remembrance, resilience, and community, headlined by Tony-nominated Broadway icons Adam Pascal and Anthony Rapp, original stars of the groundbreaking musical RENT. The event, presented by ViiV Healthcare, will take place Sunday, November 30 at Las Olas Oceanside Park, marking South Florida’s largest World AIDS Day observance. For nearly 35 years, CAN Community

• 
  Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences25 November 2025, 1:00 pm

  HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company’s management team will participate in two upcoming conferences. 8th Annual Evercore Healthcare Conference Date: December 2, 2025 Time: 8:45-9:05 am ET Format: Fireside Chat Participant: Dr. Arun Swaminathan, Ph.D., Chief

• 
  Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference25 November 2025, 12:30 pm

  BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 am ET in Miami, Florida. A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company’s website at www.vera

• 
  Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference25 November 2025, 12:00 pm

  CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p

• 
  Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting24 November 2025, 5:00 pm

  BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, will be presented in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando,

• 
  Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches24 November 2025, 11:45 am

  RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to advancing clinical research in hematology across Merck’s expanding and diverse pipeline of investigational candidates,

• 
  Imperative Care Presents Positive Real-World Data from Ischemic Stroke Patients Treated with ADAPT 2.0 Using the Zoom Stroke System21 November 2025, 9:15 pm

  CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care announces late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0.

No Feed

No Feed

No Feed

No Feed

No Feed